TFRC and breast carcinoma: Our previous study showed that the iron chelator DFO depleted the iron levels in non-aggressive ERα-positive breast cancer cells but resulted in increased iron levels by upregulating the expression of TfR1 and DMT1 in aggressive triple-negative breast cancer cells [23].